Docstoc

CanBiotech 2004 Venture Capital Directory Profiles

Document Sample
CanBiotech 2004 Venture Capital Directory Profiles Powered By Docstoc
					Atlas Venture, Inc.

Address:                      About Us
890 Winter Street Suite 320   Atlas Venture is the leading international early-stage venture
Waltham, MA 02451             capital firm, investing in communications, information
UNITED STATES                 technology and life sciences companies. Atlas Venture has
Map It                        investing offices in Boston, London, Menlo Park, Munich, Paris
                              and Seattle, and its investments are evenly divided between
                              the United States and Europe.
Contact Info:
T: (781) 622-1700             Founded in 1980, Atlas Venture has organized six international
F: (781) 622-1701             funds, and currently manages more than $2.4 billion in
E: boston@atlasventure.com    committed capital.

Company Contacts:             The Life Sciences investment team offers portfolio companies
Peter Barrett                 expertise in biotechnology licensing and marketing, business
Boston                        management, and medical practice.

Jean-François Formela         Preferred Stage
Boston                        Many of Atlas Venture’s Life Sciences portfolio companies are
                              developing new platform technologies to leverage the data
Paul Pospisil                 generated from the human genome project and enhance the
Boston                        drug discovery process. Others are developing new medical
                              devices, or using the Internet to streamline drug development
                              and healthcare delivery.
Website URL:
www.atlasventure.com/         Geographic Focus
                              With more than twenty years in international venture
Other Locations               investing, the Atlas Venture team has developed a vast
1201 Third Avenue             international network of business contacts to help portfolio
Suite 5450                    companies make connections quickly. With offices and local
Seattle, WA 98101, USA        contacts in major American and European markets, can
                              provide practical assistance to companies expanding
t: +1 206 694 8600            operations to other countries.
f: +1 206 254 9130
e: seattle@atlasventure.com   Capital
                              More than $2.4 billion in committed capital

                              Investment Portfolio
                              Acambis Plc, Achillion Pharmaceuticals, Inc, Actelion
                              Pharmaceuticals Ltd, Akceli, Inc, Allelix Biopharmaceuticals
                              Inc, Alnylam Pharmaceuticals, Inc., Anadys Pharmaceuticals,
                              Archemix Corp, ArQule, Inc, Artemis Pharmaceuticals GmbH,
                              Aureon Biosciences, Axovan Ltd., Boston Medical Technologies,
                              Inc CellZome GmbH, Ciphergen Biosystems, Inc, CropDesign
                              NV, Crucell NV, deCODE genetics, Inc, DeveloGen AG, EntoMed
                              SA, Exelixis, Inc, Hexagen Plc, Immuno-Designed Molecules
                              SA, IsoTis NV, Kriton Medical, MediGene AG, Microcide, Inc,
                              Micromet AG, Modex Therapeutiques SA, MorphoSys AG,
                              Neurochem, Inc, Neurotech SA, Newron Pharmaceuticals,
                              Novuspharma S.p.A., NxStage Medical, Oxford GlycoSciences
                              Plc, Percardia Inc, Prolifix Ltd, Renovo, Ltd, Signature
                              BioScience, Inc, Structural GenomiX, Inc, Transfusion
                              Technologies, Inc, Variagenics, Inc, Vasca, Inc
Canadian Medical Discoveries Fund
Inc.

Address:                            About Us
Talbot Centre                       Canadian Medical Discoveries Fund Inc. (CMDF) and Candian
148 Fullarton Street, Suite 2006    Medical Discoveries Fund II Inc. (CMDF II) are labour-
London, ON N6A 5P3                  sponsored investments funds (LSIFs) that focus exclusively on
CANADA                              the burgeoning health science sector.
Map It
                                    Preferred Stage
                                    The selection of early stage investments are influenced by the
Contact Info:                       following criteria:
T: (519) 858-1582
F: (519) 858-9121                   The credibility of the principal investigators;
E: information@cmdf.com             the uniqueness of the discovery;
                                    the protectability of the intellectual property under
Company Contacts:                   development; and
Dr. Calvin R. Stiller               the commercial potential of the discovery.
Chairman & CEO
                                    Capital
Michael Callaghan                   CMDF was established in 1994, and now has venture capital
Managing Director & Senior Vice     investments in over 40 companies in the life sciences sector
President                           (mostly biotechnology, along with medical devices and health
                                    services companies). The Fund has $311.6 million under
                                    management as of September 30, 2002.
Website URL:
www.cmdf.com/                       CMDF II is qualified for sale in Ontario and may be purchased
                                    only by residents of Ontario. CMDF II was established on
                                    August 31, 2002 with the amalgamation of two funds, CMDF
                                    Venture Fund and CMDF Early Stage Fund, into one larger
                                    fund, Canadian Medical Discoveries Fund II Inc.

                                    CMDF typically provides equity financing in the range of
                                    $250,000 to $5.0 million. No more than 10% of the capital
                                    raised can be invested outside of Canada.

                                    Investment Portfolio
                                    CMDF:
                                    Aegera Therapeutics, AnorMED, Biomarin Pharmaceuticals,
                                    Cellegy Pharmaceuticals, Centaur Pharmaceuticals, CryoCath
                                    Technologies, Cubist Pharmaceuticals, Cytochroma, Ecopia
                                    BioSciences, Excel-Tech Ltd., Gemin X Biotechnologies, GenSci
                                    Regeneration Sciences, Genzyme Molecular Oncology,
                                    GlycoDesign, Hemosol, MedInnova Partners, MedTech
                                    Partners, MethylGene, Microbix Biosystems, Micrologix Biotech,
                                    Networc Health, Neurocrine Biosciences, NeuroMed
                                    Technologies, Neuroscience Development Partners, Nexia
                                    Biotechnologies, NPS Pharmaceuticals, OptiMol, PhageTech,
                                    Phytogen Life Sciences, Protiva Biotherapeutics, Star Biotech,
                                    StressGen Biotechnologies, Systems Xcellence, T2C2, Tm
                                    Bioscience, Twinstrand Therapeutics, UltraVision, University
                                    Medical Discoveries, Variagenics, Veracel, WV CMDF Queen’s
                                    Scientific Breakthrough Fund, Xillix Technologies
Cambridge Gateway Fund

Address:                         About Us
Richmond House                   The Cambridge Gateway Fund invests in emerging technology
16-20 Regent Street              companies.
Cambridge, CB2 1DB
ENGLAND                          Preferred Stage
Map It                           Most investments are made in the early stages of a
                                 company's existence. Will generally be the first or joint first
                                 venture capital investor in a company.
Contact Info:
T: +44 (0)1223 720 300           Geographic Focus
F: +44 (0)1223 720 330           A UK based company- have investments in Manchester and in
E: info@cambridgegateway.com     Dunfermline, Scotland as well as in and around Cambridge.
                                 While in general, prefers to be geographically close to
Company Contacts:                portfolio.
Dr Catherine Beech
Founder and Director             Capital
E: cbeech@cambridgegateway.com   Currently have £35.3 million at cost under management.

                                 Cambridge Gateway Fund's investment in each company
Website URL:                     ranges from £1 to £3 million over the life of the investment.
www.cambridgegateway.com         Will lead an investment or support a lead investor as part of a
                                 syndicate.

                                 Investment Portfolio
                                 Cambridge BioTechnology Limited, De Novo Pharmaceuticals
                                 Limited, Intercytex Limited

                                 Investor Cross Search
                                 Click on the company name to see other investors in the
                                 company.
                                 Cambridge BioTechnology, De Novo Pharmaceuticals,
                                 Intercytex
BioMed Venture AG

Address:                       About Us
Breite Straße 6 - 8            Provides finance for promising, young life science companies
Hannover, D-30159              at every stage of their development, encouraging the planned
GERMANY                        growth of successful businesses.
Map It
                               Preferred Stage
                               Pre-seed / seed capital
Contact Info:                  Start-up financing
T: +49 (0) 511/35 39 65-0      Finance for business expansion
F: +49 (0) 511/35 39 65-44     Pre-IPO financing
E: info@biomed-venture.de      Bridge financing

Company Contacts:              Investment Portfolio
Willi Weddrin                  MicroNet Medical Inc. , *Acri.Tec GmbH, AdnaGen AG,
CEO                            BioVisioN GmbH & Co. KG, Cranium Telemetrics, Intelligent
E: weddrin@biomed-venture.de   Ion, Inc., Mesotec GmbH, St. Croix Medical, Excorp Medical

Uwe Hofmann                    Investor Cross Search
CEO                            Click on the company name to see other investors in the
E: hofmann@biomed-venture.de   company.
                               Acri.Tec, AdnaGen, BioVisioN, Cranium Telemetrics, Excorp
Dr. Angelika Vlachou           Medical, Intelligent Ion, Mesotec, MicroNet Medical, St. Croix
Investment Manager             Medical
E: vlachou@biomed-venture.de

Dr. Kristina Felner
Investment Manager
E: felner@biomed-venture.de


Website URL:
www.biomed-venture.de/

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:2
posted:10/21/2011
language:English
pages:4